QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)

ACADIA Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACAD)

$20.91
-0.88 (-4.04%)
(As of 01:57 PM ET)
Compare
Today's Range
$20.87
$21.73
50-Day Range
$20.78
$24.07
52-Week Range
$14.48
$33.99
Volume
686,448 shs
Average Volume
1.54 million shs
Market Capitalization
$3.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.67

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
65.9% Upside
$35.67 Price Target
Short Interest
Bearish
4.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.82 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to $0.94 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

188th out of 960 stocks

Pharmaceutical Preparations Industry

47th out of 378 stocks


ACAD stock logo

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

ACAD Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
StockNews.com Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) to Hold
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
ACADIA Pharmaceuticals Inc ACAD
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.67
High Stock Price Target
$95.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+63.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-20.83%

Debt

Sales & Book Value

Annual Sales
$631.89 million
Book Value
$2.47 per share

Miscellaneous

Free Float
119,031,000
Market Cap
$3.58 billion
Optionable
Optionable
Beta
0.59
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price target for 2024?

12 equities research analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $15.00 to $95.00. On average, they anticipate the company's share price to reach $35.67 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD shares have increased by 35.1% and is now trading at $21.50.
View the best growth stocks for 2023 here
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The biopharmaceutical company had revenue of $211.70 million for the quarter, compared to analysts' expectations of $194.40 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 38.84% and a negative net margin of 23.55%.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (7.05%), FMR LLC (3.23%), Fred Alger Management LLC (1.89%), Morgan Stanley (1.13%), Emerald Advisers LLC (1.03%) and Jacobs Levy Equity Management Inc. (0.87%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -